Harvard Bioscience (HBIO) has provided an announcement.
Harvard Bioscience, Inc.’s Compensation Committee has recently greenlit the 2024 annual cash incentive plan, setting up a substantial performance-based earning potential for their CEO and CFO. Each executive has a target award pegged as a percentage of their base salary, with the chance to earn up to 150% of that target by meeting specific corporate financial goals.
For an in-depth examination of HBIO stock, go to TipRanks’ Stock Analysis page.
